CAMBRIDGE, Mass., March 31 /PRNewswire/ -- Microbia, Inc. today announced the appointment of Halley Gilbert to the position of vice president, general counsel. In this newly created position, Ms. Gilbert will manage the legal department and direct all legal matters.
(Logo: http://www.newscom.com/cgi-bin/prnh/20070917/NYM031LOGO )
“We are very pleased to have Halley join the Microbia team,” said Peter Hecht, CEO of Microbia. “Her extensive legal experience in the pharmaceutical and biotechnology industries will be critical to us as we commercialize our clinical compounds over the next few years.”
Gilbert joins Microbia with 13 years of corporate law experience. Most recently, she was with Cubist Pharmaceuticals, Inc. where she was vice president and deputy general counsel. At Cubist, she led legal efforts relating to securities, employment and benefits, clinical development, regulatory, sales and marketing, and manufacturing. She was named Cubist “Employee of the Year” in 2006. Prior to her position at Cubist, Gilbert served as corporate counsel with Genzyme Corporation and was an associate with the law firm of Skadden, Arps, Slate, Meagher & Flom, LLP, specializing in securities law and mergers and acquisitions.
“I have been very impressed with Microbia’s ability to deliver results,” said Halley Gilbert. “The company’s innovative discovery and development portfolio has the potential to help a large number of patients. I look forward to working with Microbia’s great team to help the company build on its success to date.”
Gilbert received her J.D. from Northwestern University School of Law, and a B.A. in political science from Tufts University. In 2007, Gilbert was recognized by the Boston Business Journal as one of the top “40 under 40" business leaders in the Boston area.
About Microbia
Microbia (www.microbia.com) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. The Company is advancing several clinical candidates-linaclotide for the treatment of irritable bowel syndrome with constipation, chronic constipation and other functional gastrointestinal disorders; and novel, next-generation cholesterol absorption inhibitors for the treatment of hypercholesterolemia. Microbia also has a growing pipeline of additional drug candidates in earlier stages of development. Microbia Precision Engineering, Inc., a majority-owned subsidiary of Microbia, Inc., is an industrial biotechnology company developing and commercializing novel bioprocesses for the production of specialty chemicals. Microbia has raised $231 million in private equity financing and is located in Cambridge, Massachusetts.
sbrady@microbia.com
CONTACT: Susan Brady, Corporate Communications, Microbia, Inc.,
+1-617-621-8304, sbrady@microbia.com
Web site: http://www.microbia.com//
